INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Nagendran Sukumar reported TSHA

Director, President and Head of R&D · Taysha Gene Therapies, Inc. · Taysha Gene Therapies, Inc. — Employee Stock Option (right to buy)

Side
M
Value
—
Shares
88.7K
Price
—
Executed
Jan 12, 2026
Disclosed
Jan 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 12 executedJan 14, 2026 disclosed

TSHA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
7/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 23.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TSHA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M—
    19.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$33K
    19.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    11
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$892K
    200.0K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    32
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$423K
    89.1K sh
    		Jan 23, 2026Jan 27, 2026
    traded Jan 23, 2026
    		+4dSEC FORM 4

    Evidence

    25
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$124K
    26.9K sh
    		Jan 26, 2026Jan 27, 2026
    traded Jan 26, 2026
    		+1dSEC FORM 4

    Evidence

    36
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$375K
    79.0K sh
    		Jan 23, 2026Jan 27, 2026
    traded Jan 23, 2026
    		+4dSEC FORM 4

    Evidence

    25
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Open-market sale
    		SELL$110K
    23.8K sh
    		Jan 26, 2026Jan 27, 2026
    traded Jan 26, 2026
    		+1dSEC FORM 4

    Evidence

    6
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$152K
    88.7K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$942K
    200.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    7
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Grant or award · 10b5-1 plan
    		A—
    427.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    11
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M—
    111.3K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    0
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Grant or award · 10b5-1 plan
    		A—
    274.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    NP
    Nolan Sean P.Director, Chief Executive Officer
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    1.01M sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    NP
    Nolan Sean P.Director, Chief Executive Officer
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    648.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    17
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    359.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AK
    Alam KamranCHIEF FINANCIAL OFFICER
    TSHATaysha Gene Therapies, Inc.
    Grant or award
    		A—
    231.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    6
    NS
    Nagendran SukumarDirector, President and Head of R&D
    TSHATaysha Gene Therapies, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    111.3K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001665124-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 12, 2026
    Published
    Jan 14, 2026
    Ingested by INSIDER
    Nov 5, 04:22 UTC
    Last re-read
    Nov 5, 04:22 UTC

    Extracted facts

    Filer
    Nagendran Sukumar
    Role
    Director, President and Head of R&D
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Taysha Gene Therapies, Inc. — Employee Stock Option (right to buy)
    Ticker
    TSHA
    Shares
    88.7K
    Price per share
    $0
    Execution date (reported)
    Jan 12, 2026
    Owned after transaction
    474.9K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Nagendran Sukumar filed this Form 4 reporting a option exercise of TSHA on Jan 12, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and Head of R&D
    Nagendran Sukumarcik:0001665124
    Issuer
    Taysha Gene Therapies, Inc.cik:0001806310

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.